News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Search Results for: myeloma
1234567
Autolus Announces First-Dose Cohort Completed In APRIL Study Of AUTO2: A Phase I/II Study In Patients With Multiple Myeloma
Monday, September 18, 2017
SELLAS Life Sci' Galinpepimut-S Induces Specific, Robust And Durable Immune Responses In Patients With High-Risk Multiple Myeloma - Correlated With Clinical Benefit
Thursday, September 14, 2017
Amgen (AMGN) Release: Long-Term Analysis Of Phase III Head-To-Head Study Confirms KYPROLIS (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
Thursday, August 31, 2017
Genmab A/S (GEN.CO) Announces Positive Topline Results In Phase III ALCYONE Study Of Daratumumab In Front Line Multiple Myeloma
Thursday, August 24, 2017
Unum Announces Active Investigational New Drug (IND) Application For ACTR087 In Combination With SEA-BCMA In Patients With Relapsed/Refractory Multiple Myeloma
Wednesday, August 23, 2017
PharmaMar Starts A Quadruple Combination Study With Aplidin For The Treatment Of Multiple Myeloma
Wednesday, August 09, 2017
Cellectar Biosciences  (CLRB)’ CLR 131 Achieves Overall Survival Of Greater Than 22 Months In Advanced Multiple Myeloma Patients
Tuesday, August 08, 2017
SkylineDx Researchers Publish Data Demonstrating Utility Of SKY92 As Prognostic Tool In Multiple Myeloma (MM)
Tuesday, July 25, 2017
Amgen (AMGN) Release: Second Phase III Study Shows Kyprolis (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
Thursday, July 13, 2017
Multiple Myeloma Research Foundation (MMRF) Announces $15 Million Investment In Immunotherapy Initiative
Thursday, June 29, 2017
Bristol-Myers Squibb (BMY) Release: Four-Year Follow-Up With Empliciti (Elotuzumab) Plus Lenalidomide/Dexamethasone (Eld) In Patients With Advanced Multiple Myeloma Shows Long-Term Efficacy In ELOQUENT-2 Trial
Monday, June 26, 2017
Takeda (TKPYY) Presents Data From Phase I/II Studies For NINLARO (Ixazomib) In Newly Diagnosed Multiple Myeloma Patients And In The Maintenance Setting
Friday, June 23, 2017
Adaptive Biotech Announces A Collaboration With Janssen Biotech (JNJ) To Use The clonoSEQ? Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX? Multiple Myeloma Trials
Thursday, June 22, 2017
Adaptive Biotech Announces A Collaboration With Janssen Biotech (JNJ) To Use The Clonoseq Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX Multiple Myeloma Trials
Wednesday, June 21, 2017
Data Presentations At European Hematology Association 22nd Annual Congress Further Validate SkylineDx Prognostic Tools In Multiple Myeloma
Tuesday, June 20, 2017
1234567
//-->